2020 News
Rutgers Senior Explored how Fish became Land Creatures
- April 30, 2020
Rutgers Senior Explored how Fish became Land Creatures
Arriving from England, he was drawn to genetics lab
Growing up in England, Thomas Wood took an early interest in healing sick animals.
His neighbor in the town of Orpington, on the southeastern edge of London, was a veterinarian who showed eight-year-old Thomas how to nurse a pair of ailing cats.
“She had two very sick cats and would invite me round to show me what was wrong,” Wood says. “One of them had a really bad abscess and I cleaned out the wound.”
Inspired, Wood set out on a path toward veterinary college. But his budding passion for science and research eventually led him to an entirely different destination: The Department of Genetics at Rutgers University–New Brunswick.
Wood, now a School of Arts and Sciences Honors Program senior in the Class of 2020, is finishing up a remarkable undergraduate odyssey. He routinely logged up to 35 hours a week in the lab of Tetsuya Nakamura, a professor who studies the fish-to-tetrapod transition that occurred some 400 million years ago.
He has been accepted into the Genetics and Development doctoral program at Columbia University.
"Although my senior year has been cut short by the COVID-19 pandemic, my Rutgers experience has been amazing," he says. “I had the opportunity to study the topic that fascinates me and get excellent preparation for graduate school.”
At Rutgers, Wood's main research interest was in the genetic mechanisms that allowed fish to evolve into land vertebrates such as mammals, birds, and reptiles.
“It’s a crucial transition,” Wood says. “There were many fundamental changes that had to occur and that continue to shape our lives today."
Working with Nakamura, Wood contributed to the available knowledge in his field. He co-authored a review paper with Nakamura that was published in the journal Frontiers in Cell and Developmental Biology.
In the article, the two write how state-of-the-art techniques in molecular biology and imaging are serving to expand our understanding of the genetics involved in the transition.
In the lab, Wood uses reverse genetic approaches and CT scans to identify the genes and molecular pathways involved in the origin of the neck. By “turning off” certain genes, he says, sample fish began to lose the solid connection that fuses the skull to the body, creating a gap in which a neck could develop.
Thomas Wood, majoring in genetics, is getting ample research opportunities in a lab that explores the fish-to-tetrapod transition.“I am specifically looking at the making of the bridge between the skull and the rest of the body that became the neck and parts of the shoulder and scapula,” Wood says. “Expanding our knowledge of developmental pathways in humans is beneficial in many ways, including for understanding health, such as providing important information for the study of bone diseases.”
Wood’s own evolution—from aspiring veterinarian to genetics researcher—took hold naturally from his early interactions with veterinary surgeons. He found himself fascinated by genetic techniques such as polymerase chain reaction, or PCR, which is used to copy DNA or RNA samples for analysis.
“It was clear that these basic techniques could push the boundaries of what we know about medicine and genetic diseases,” he says.
As it became evident that his interests went beyond veterinary science, one of the scientists he was working with in England advised him to seek out an American research university.
“And it just so happened that my guidance counselor received an email from Rutgers expressing interest in students and offering to help facilitate the process,’’ he said. “This set me on my 3,500 mile long path away from veterinary medicine in the UK to the genetics program here at Rutgers.”
It is a journey he is happy he made. The Department of Genetics, like others in the life sciences, offers ample opportunity for undergraduate research.
“It has been a fantastic situation,” Wood says.
He wrote his senior honors thesis on "The Evolutionary Origin of the Neck: The Genetic Mechanisms Behind Girdle Development and Evolution in Zebrafish."
He also found himself right at home with the range of activities available at Rutgers. He got involved with the Association of Undergraduate Geneticists, the Filipino Martial Arts Club, and Leadership and Experiential Learning.
Wood also received the Enrico P. Veltri Scholarship for the Life Sciences and the Duncan and Nancy Macmillan Award for Research Excellence.
Why Do So Many Pregnancies and In Vitro Fertilization Attempts Fail?
- April 13, 2020
Why Do So Many Pregnancies and In Vitro Fertilization Attempts Fail?
Scientists’ new model may lead to more ways to improve fertility
Scientists have created a mathematical model that can help explain why so many pregnancies and in vitro fertilization attempts fail.
The Rutgers-led study, which may help to improve fertility, is published in the journal Proceedings of the National Academy of Sciences.
Mistakes in female meiosis, the cell division process that creates egg cells, result in eggs with an abnormal number of chromosomes (too many or too few). This phenomenon is strongly associated with the repeated loss of pregnancies and the failure of in vitro fertilization (IVF) procedures, as well as developmental disorders such as Down syndrome.
“Our study demonstrates that in the future, mathematical models can be powerful tools for predicting the outcomes of in vitro fertilization for infertility patients and/or provide the basis for considering alternative family planning options, such as adoption,” said senior author Jinchuan Xing, an associate professor in the Department of Genetics in the School of Arts and Sciences and at the Human Genetics Institute of New Jersey at Rutgers University–New Brunswick.
“Modeling efforts such as ours can provide guidelines on, for instance, how many eggs must be collected during a single IVF cycle to ensure there will be at least one chromosomally normal conception,” said co-author Karen Schindler, an associate professor in the Department of Genetics and at the Human Genetics Institute of New Jersey.
Pregnancy loss is extremely common, with nearly 20 percent of clinically recognized pregnancies resulting in miscarriage, and many more unrecognized pregnancies end earlier, the study notes.
Chromosomes in an egg. Modeling can help predict how many eggs should be retrieved for in vitro fertilization to lead to a normal, successful pregnancy. Image: Cecilia Blengini and Kristen DriscollA leading cause of early miscarriage is called aneuploidy, when eggs have the wrong number of chromosomes, and it’s also the main cause of IVF failure. The vast majority of eggs with chromosome problems are linked to errors in female cell division that increase as women age. Understanding how that happens is crucial because the average age at conception is rising in developed countries.
“Such basic knowledge is required to pave the way for future diagnostic and therapeutic innovations to improve human fertility,” the study says.
The scientists developed a mathematical model describing all possible abnormal chromosome count issues in eggs due to cell division errors. Using data on 11,157 early stage human embryos (blastocysts), the model revealed previously unknown patterns of errors.
The model can be used to identify IVF patients who produce an extreme number of abnormal embryos. It’s also a powerful tool for understanding why abnormal numbers of chromosomes arise when cells divide and for predicting the outcomes of IVF reproduction. The model potentially could provide guidance for clinicians on the expected number of IVF cycles needed to get a normal conception for each patient. The modeling framework can also be expanded and adapted to address other processes, such as predicting errors in sperm.
The lead author is Katarzyna M. Tyc, a former Rutgers post-doctoral associate now at Virginia Commonwealth University. A scientist at Johns Hopkins University contributed to the study.
Read the story on Rutgers Today.
New Rutgers Saliva Test for Coronavirus Gets FDA Approval
- April 13, 2020
New Rutgers Saliva Test for Coronavirus Gets FDA Approval
Emergency use authorization granted for new biomaterial collection approach
The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Rutgers’ RUCDR Infinite Biologics and its collaborators for a new collection approach that utilizes saliva as the primary test biomaterial for the SARS-CoV-2 coronavirus, the first such approval granted by the federal agency.
The new saliva collection method, which RUCDR developed in partnership with Spectrum Solutions and Accurate Diagnostic Labs (ADL), will allow for broader population screening than the current method of nose and throat swabs.
“The impact of this approval is significant,” said Andrew Brooks, chief operating officer and director of technology development at RUCDR, who also is a professor in the School of Arts and Sciences Department of Genetics at Rutgers University–New Brunswick. “It means we no longer have to put health care professionals at risk for infection by performing nasopharyngeal or oropharyngeal collections. We can preserve precious personal protective equipment for use in patient care instead of testing. We can significantly increase the number of people tested each and every day as self-collection of saliva is more quick and scalable than swab collections. All of this combined will have a tremendous impact on testing in New Jersey and across the United States.”
Soon after the Rutgers-ADL team received notification from the FDA on Saturday, the White House’s COVID-19 testing task force called Brooks to offer congratulations and support and to ask about any specific hurdles to expanding testing and enabling other laboratories to benefit from the accomplishment.
Shortly after the White House call, the research team was contacted by chief executive officers of some of the world’s largest life sciences companies that are involved in COVID-19 testing.
“I have spoken with these companies’ leadership to not only share knowledge but to create opportunities for continuing to help innovate during this crisis,” Brooks said. “We will work closely with these new partners, the FDA and the White House task force to leverage everything Rutgers has to offer to not only help our community but also make a global impact.”
Rutgers University President Robert Barchi called the new saliva test a “herculean effort that is great for the country and the world and by reflection great for our university.”
“Saliva testing will help with the global shortage of swabs for sampling and increase testing of patients, and it will not require health care professionals to be put at risk to collect samples,” Brooks said. “Saliva testing will also be important for people who are in quarantine because they don’t know how long it will be until they are no longer infectious. This will allow health care workers to release themselves from quarantine and safely come back to work.”
“The test can help hospital-based and private physicians to accurately assess the infection status of more patients, with RUCDR Infinite Biologics doing the analysis,” said Jay A. Tischfield, the founder, chief executive officer and scientific director of RUCDR and a Distinguished Professor also in the Department of Genetics at Rutgers–New Brunswick and at Rutgers Robert Wood Johnson Medical School.
“Rutgers is proud to be on the cutting edge of the fight against the COVID-19 pandemic,” said Rutgers Biomedical and Health Sciences Chancellor Brian Strom. “We have long said our researchers and health care employees are working to help make the world well, but never has it been more true than now.”
Rutgers University–New Brunswick Chancellor Chris Molloy agrees. “Rutgers has always been on the leading edge of research and discovery. We are proud of the work we do and the positive impact it has on the world.”
The FDA’s approval of the new saliva testing approach is the second major announcement in recent days from RUCDR, which launched a genetic testing service for the coronavirus that can test thousands of samples daily. With the new saliva test, that number may increase to tens of thousands of samples daily.
The tests are available to the RWJBarnabas Health network, which has partnered with Rutgers University and is New Jersey’s most comprehensive health care system, including Robert Wood Johnson University Hospital, University Hospital in Newark and many other facilities, including several county health departments. Starting Wednesday, Rutgers, in partnership with the Middlesex County government and RWJBarnabas Health, will make the test available to county residents at a drive-thru testing facility at 33 Kilmer Road, Edison, New Jersey.
ABOUT RUCDR INFINITE BIOLOGICS
RUCDR Infinite Biologics, which is part of Rutgers’ Human Genetics Institute of New Jersey, is the world’s largest university-based cell and DNA repository. Its mission is to understand the genetic causes of common, complex diseases and to discover diagnoses, treatments and cures for them. The organization collaborates with researchers in the public and private sectors throughout the world, providing the highest quality bio-banking services and biomaterials, as well as scientific and technical support
ABOUT SPECTRUM SOLUTIONS AND SPECTRUM DNA
Headquartered in Salt Lake City, Utah, Spectrum Solutions and its medical device and services division, Spectrum DNA, focus on innovative, end-to-end product development, manufacturing, and global fulfillment solutions. With concentrated industry expertise, Spectrum DNA specializes in engineering innovative molecular diagnostic solutions that simplify the biosample collection process while offering donors complete physical and digital chain-of-custody. With on-site production facilities, we are a single-source provider of full-service medical device manufacturing, custom and private label packaging, kitting, and direct-to-donor global fulfillment. Our new biosample collection devices, patented technology, and services provide measurable process optimization, unprecedented efficiency, and unmatched global scalability. For more information, please visit www.spectrum-dna.com.
ABOUT ACCURATE DIAGNOSTIC LABS
Accurate Diagnostic Labs is one of the largest privately held, boutique, full-service clinical laboratories in the country. ADL, as a full-service core laboratory, proudly works with various entities on laboratory testing for clinical trial drug development and data repository in various market footprints to progress the field of disease state management and personalized medicine. With our local headquarters based in Central New Jersey, we pride ourselves in working with various healthcare corporations, institutions, health systems, and the local providers in the metropolitan area with the common goal of improving local and national healthcare. For more information on ADL, please call at 732-839-3300 or visit online at www.accuratediagnosticlabs.com.
Read the story on Rutgers Today
Rutgers Launches Genetic Testing Service for New Coronavirus
- April 1, 2020
Rutgers Launches Genetic Testing Service for New Coronavirus
Thousands of samples can be analyzed daily
Rutgers’ RUCDR Infinite Biologics has launched a test for the SARS-CoV-2 coronavirus and is using its automation experience and infrastructure to test as many as tens of thousands of samples daily.
RUCDR has also submitted an emergency use authorization request for a saliva collection method that will allow for broader population screening.
The RUCDR effort, which significantly increases the much-needed testing capacity in New Jersey, will provide information that allows people who test positive to self-quarantine, thus limiting the spread of the virus. In addition, health care providers, first responders and others will be able to quickly and safely return to work after recovering from COVID-19 and testing negative.
The test is available now and based on a Nobel Prize-winning laboratory technique that makes millions of copies of the SARS-CoV-2 virus nucleic acid (in this case RNA) in a sample. Testing a nasal or throat swab sample determines whether someone is infected, with results available to providers within three days. Saliva testing would be a new development and would allow testing without the need of a medical provider to take the sample.
The rapid deployment of the test throughout the state is a consequence of a partnership between RUCDR and Accurate Diagnostic Labs (ADL). RUCDR and ADL have a long-standing relationship where ADL provides reference lab services for RUCDR, which facilitates clinical trials that RUCDR supports. RUCDR, in conjunction with ADL’s clinical client base, fast-tracked the validation and verification of new testing methodologies, including saliva, for SARS-CoV-2 COVID-19. These alternate collection options will catapult access of testing and screening to the most needed population.
The test is currently available to the RWJBarnabas Health network, which has partnered with Rutgers University and is New Jersey’s most comprehensive health care system, and includes Rutgers Robert Wood Johnson University Hospital, University Hospital in Newark and many other facilities including several county health departments.
“We can accept hundreds to thousands of samples for analysis per day now and potentially will be able to test tens of thousands of samples daily in the next several weeks,” said Andrew I. Brooks, chief operating officer and director of technology development at RUCDR Infinite Biologics. He is also a professor in the Department of Genetics in the School of Arts and Sciences at Rutgers University–New Brunswick.
“Saliva testing will help with the global shortage of swabs for sampling and increase testing of patients, and it will not require health care professionals to collect samples,” Brooks said. “Saliva testing will also be important for people who are in quarantine because they don’t know how long it will be until they are no longer infectious. This will allow health care and workers to release themselves from quarantine and safely come back to work.”
“The test can help hospital-based and private physicians to accurately assess the infection status of more patients, with RUCDR Infinite Biologics doing the analysis,” said Jay A. Tischfield, founder, chief executive officer and scientific director of RUCDR Infinite Biologics and a Distinguished Professor in the Department of Genetics at Rutgers–New Brunswick and at Rutgers Robert Wood Johnson Medical School.
RUCDR Infinite Biologics, which is part of Rutgers’ Human Genetics Institute of New Jersey, is the world’s largest university-based cell and DNA repository. Its mission is to understand the genetic causes of common, complex diseases and to discover diagnoses, treatments and cures for them. The organization collaborates with researchers in the public and private sectors throughout the world, providing the highest quality bio-banking services and biomaterials, as well as scientific and technical support.